DJIA 18,011.94 -28.43 -0.16%
NASDAQ 5,076.52 -6.41 -0.13%
S&P 500 2,109.60 -2.13 -0.10%
market minute promo

Roche Holding Ltd. (ADR) (NASDAQOTH: RHHBY)

36.84 -0.16 (-0.43%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

RHHBY $36.84 -0.43%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $36.93
Previous Close $37.00
Daily Range $36.74 - $37.01
52-Week Range $32.08 - $38.54
Market Cap $207.1B
P/E Ratio 0.00
Dividend (Yield) $0.00 (2.2%)
Volume 968,248
Average Daily Volume 833,510
Current FY EPS $1.87

Sector

Healthcare

Industry

Pharma

Roche Holding Ltd. (ADR) (RHHBY) Description

Website:

News & Commentary

Why ImmunoGen Inc.'s Stock Soared Today

Shares of the struggling biopharma ImmunoGen skyrocketed today following a clinical update at the American Society of Clinical Oncology meeting. Here's what you need to know moving forward.

3 Stocks That Could Double Your Money

Biotech has produced numerous stocks recently that have doubled or tripled in short periods of time. Here is a look at three small-cap companies with the potential to continue this trend.

5 Largest Markets for Pharmaceuticals

The pharmaceutical market is headed for $1.3 trillion by 2016. Here's how globalization is radically changing the game for Big Pharma and Big Biotech players.

Regeneron Earnings Shine, but All Eyes Are on the Pipeline

Regeneron topped estimates Thursday as Eylea sales continue to soar. But the stock failed to hold its gains, as all eyes appear to now be on the biotech's pipeline.

The Best Fidelity Mutual Funds

What are Fidelity's top funds nowadays? Here are nine choices delivering strong performance.

Why ImmunoGen Inc. Shares Tumbled Today

After reporting first-quarter financials Friday, ImmunoGen Inc.'s shares fell despite bullish analyst reports.

3 Soaring Biotech Stocks Under $10 -- Are They Buys?

Here's what you should know about Exelixis Inc., Corcept Therapeutics, and Array BioPharma's big moves this year.

Is Immuno-Oncology the Best Area of Biotech to Invest in Right Now?

Immuno-oncology has become a major focus among big pharma companies these days. Should investors jump on this trend?

Best Pure Play Investment in Cancer Drugs

Global cancer drug sales could soon soar past $100 billion, making this pure play in cancer drugs a stock you should seriously consider owning.

3 Promising Healthcare Stocks Under $10

Healthcare stocks with plenty of potential -- and low share prices

See More RHHBY News...

RHHBY's Top Competitors

RHHBY $36.84 (-0.43%)
Current stock: RHHBY
JNJ $99.98 (-0.06%)
Current stock: JNJ
NVS $102.94 (-0.33%)
Current stock: NVS
GSK $44.24 (0.20%)
Current stock: GSK